ILMN Quote, Financials, Valuation and Earnings

Guardant Health, Inc. has a net margin of 13.85% compared to Illumina, Inc.'s net margin of -34.97%. Illumina, Inc.'s return on equity of 30.55% beat Guardant Health, Inc.'s return on equity of -8518.58%.

Illumina, Inc. has a consensus price target of $125.28, signalling downside risk potential of -4.49%. On the other hand Guardant Health, Inc. has an analysts' consensus of $114.05 which suggests that it could grow by 11.66%. Given that Guardant Health, Inc. has higher upside potential than Illumina, Inc., analysts believe Guardant Health, Inc. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.409, which suggesting that the stock is 40.855% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.584, suggesting its more volatile than the S&P 500 by 58.44%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.1B, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. Illumina, Inc.'s net income of $150M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, Illumina, Inc.'s price-to-earnings ratio is 29.39x while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.82x versus 14.05x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of 13.85% compared to Illumina, Inc.'s net margin of -14.78%. Illumina, Inc.'s return on equity of 30.55% beat Natera, Inc.'s return on equity of -26.6%.

Illumina, Inc. has a consensus price target of $125.28, signalling downside risk potential of -4.49%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 7.5%. Given that Natera, Inc. has higher upside potential than Illumina, Inc., analysts believe Natera, Inc. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.409, which suggesting that the stock is 40.855% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.620, suggesting its more volatile than the S&P 500 by 61.981%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.1B, which are larger than Natera, Inc. quarterly revenues of $592.2M. Illumina, Inc.'s net income of $150M is higher than Natera, Inc.'s net income of -$87.5M. Notably, Illumina, Inc.'s price-to-earnings ratio is 29.39x while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.82x versus 14.60x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Waters Corp. has a net margin of 13.85% compared to Illumina, Inc.'s net margin of 18.62%. Illumina, Inc.'s return on equity of 30.55% beat Waters Corp.'s return on equity of 32.82%.

Illumina, Inc. has a consensus price target of $125.28, signalling downside risk potential of -4.49%. On the other hand Waters Corp. has an analysts' consensus of $406.34 which suggests that it could grow by 6.98%. Given that Waters Corp. has higher upside potential than Illumina, Inc., analysts believe Waters Corp. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.409, which suggesting that the stock is 40.855% more volatile than S&P 500. In comparison Waters Corp. has a beta of 1.163, suggesting its more volatile than the S&P 500 by 16.308%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waters Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Waters Corp. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.1B, which are larger than Waters Corp. quarterly revenues of $799.9M. Illumina, Inc.'s net income of $150M is higher than Waters Corp.'s net income of $148.9M. Notably, Illumina, Inc.'s price-to-earnings ratio is 29.39x while Waters Corp.'s PE ratio is 34.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.82x versus 7.30x for Waters Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings Corp. has a net margin of 13.85% compared to Illumina, Inc.'s net margin of -6.54%. Illumina, Inc.'s return on equity of 30.55% beat GeneDx Holdings Corp.'s return on equity of 0.82%.

Illumina, Inc. has a consensus price target of $125.28, signalling downside risk potential of -4.49%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $170.89 which suggests that it could grow by 31.39%. Given that GeneDx Holdings Corp. has higher upside potential than Illumina, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.409, which suggesting that the stock is 40.855% more volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.053, suggesting its more volatile than the S&P 500 by 105.339%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.1B, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Illumina, Inc.'s net income of $150M is higher than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Illumina, Inc.'s price-to-earnings ratio is 29.39x while GeneDx Holdings Corp.'s PE ratio is 2,156.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.82x versus 9.27x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.